Jeff Moehlenkamp

Senior Director, Head of Toxicology at Karuna Therapeutics
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
IN
Languages
  • English Native or bilingual proficiency
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Diplomate, American Board of Toxicology
    American Board of Toxicology
    Jan, 2006
    - Nov, 2024
  • DABT
    American Board of Toxicology, Inc.
    Jan, 2022
    - Nov, 2024

Experience

  • Karuna Therapeutics
    • United States
    • Biotechnology
    • 100 - 200 Employee
    • Senior Director, Head of Toxicology
      • Jun 2021 - Present

  • Aclairo Pharmaceutical Development Group
    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Senior Consultant
      • Jul 2018 - Jun 2021

    • Consultant
      • Nov 2016 - Jun 2018

  • Bristol Myers Squibb
    • United States
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Associate Director, DSE Business Operations
      • May 2015 - Oct 2016

    • Associate Director, Toxicology Operations
      • Mar 2012 - May 2015

    • Group Leader
      • Oct 2008 - Feb 2012

    • Manager
      • Oct 2005 - Oct 2008

    • Senior Res Investigator I
      • Oct 2004 - Oct 2005

  • Bristol Myers Squibb
    • United States
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Research Investigator II
      • Jun 2002 - Jun 2004

    • Research Investigator I
      • Jun 2000 - Jun 2002

  • University of Michigan
    • United States
    • Higher Education
    • 700 & Above Employee
    • Post-doctoral research fellow
      • Jun 1999 - May 2000

Education

  • University of Kansas Medical Center
    PhD, Pharmacology / Toxicology
    1994 - 1999
  • Butler University
    B.S., Biology
    1989 - 1993

Community

You need to have a working account to view this content. Click here to join now